Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy

Volume: 32 Number: 4 October 1, 2015
  • Melek Kandemir
  • Belgin Küçükkaya
  • Muzaffer Savaş Tepe
  • Zehra Betül Yalçıner
  • Nedret Taflan Salepçi
EN

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy

Abstract

Background: Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinicoradiologic syndrome characterized by headache, decreased alertness, seizures, visual abnormalities, and white matter changes indicative of cerebral edema. Although the pathogenesis remains poorly understood, several etiological causes have been described. RPLS is a common complication of chemotherapeutics because of its toxic effect on the central nervous system. This syndrome is frequently associated with seizures but rarely seen with status epilepticus and periodic lateralized epileptiform discharges (PLEDs). Case Report: We present a case with metastatic lung cancer that developed RPLS after carboplatin and paclitaxel therapy. Our case was admitted to the hospital with status epilepticus and her electroencephalography showed PLEDs. Conclusion: It is important to closely monitor blood pressure and electrolyte levels in patients who take chemotherapeutic agents, especially when there is no previous history of hypertension. It should be kept in mind that RPLS is a causative factor of status epilepticus and PLEDs.

Keywords

References

  1. 1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500. [CrossRef]
  2. 2. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415-7.
  3. 3. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001;12:1327-9. [CrossRef]
  4. 4. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004;77:72-6. [CrossRef]
  5. 5. Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: A case report and review of literature. Oncologist 2007;12:1332-5. [CrossRef
  6. 6. Bhatt A, Farooq MU, Bhatt S, Majid A, Kassab MY. Periodic lateralized epielptiform discharges: an initial electrographic pattern in reversible posterior leukoencephalopathy syndrome. Neurol Neurochir Pol 2008;42:55-9.
  7. 7. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiological findings. Mayo Clin Proc 2010;85:427-32. [CrossRef]
  8. 8. Imai H, Okuno N, Ishihara S, Nakano S, Higuchi S, Arai T, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. Intern Med 2012;51:911-5. [CrossRef]

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Melek Kandemir This is me

Belgin Küçükkaya This is me

Muzaffer Savaş Tepe This is me

Zehra Betül Yalçıner This is me

Nedret Taflan Salepçi This is me

Publication Date

October 1, 2015

Submission Date

October 1, 2015

Acceptance Date

-

Published in Issue

Year 2015 Volume: 32 Number: 4

APA
Kandemir, M., Küçükkaya, B., Tepe, M. S., Yalçıner, Z. B., & Salepçi, N. T. (2015). Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal, 32(4), 421-425. https://izlik.org/JA78PF87MS
AMA
1.Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal. 2015;32(4):421-425. https://izlik.org/JA78PF87MS
Chicago
Kandemir, Melek, Belgin Küçükkaya, Muzaffer Savaş Tepe, Zehra Betül Yalçıner, and Nedret Taflan Salepçi. 2015. “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”. Balkan Medical Journal 32 (4): 421-25. https://izlik.org/JA78PF87MS.
EndNote
Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT (October 1, 2015) Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal 32 4 421–425.
IEEE
[1]M. Kandemir, B. Küçükkaya, M. S. Tepe, Z. B. Yalçıner, and N. T. Salepçi, “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”, Balkan Medical Journal, vol. 32, no. 4, pp. 421–425, Oct. 2015, [Online]. Available: https://izlik.org/JA78PF87MS
ISNAD
Kandemir, Melek - Küçükkaya, Belgin - Tepe, Muzaffer Savaş - Yalçıner, Zehra Betül - Salepçi, Nedret Taflan. “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”. Balkan Medical Journal 32/4 (October 1, 2015): 421-425. https://izlik.org/JA78PF87MS.
JAMA
1.Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal. 2015;32:421–425.
MLA
Kandemir, Melek, et al. “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”. Balkan Medical Journal, vol. 32, no. 4, Oct. 2015, pp. 421-5, https://izlik.org/JA78PF87MS.
Vancouver
1.Melek Kandemir, Belgin Küçükkaya, Muzaffer Savaş Tepe, Zehra Betül Yalçıner, Nedret Taflan Salepçi. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal [Internet]. 2015 Oct. 1;32(4):421-5. Available from: https://izlik.org/JA78PF87MS